NO922604L - Pyrrolopyraziner - Google Patents
PyrrolopyrazinerInfo
- Publication number
- NO922604L NO922604L NO92922604A NO922604A NO922604L NO 922604 L NO922604 L NO 922604L NO 92922604 A NO92922604 A NO 92922604A NO 922604 A NO922604 A NO 922604A NO 922604 L NO922604 L NO 922604L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- means hydrogen
- hydrogen
- disease
- bond
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- LJWZSXDLNMOUIP-UHFFFAOYSA-N N1C=CN=C2N=CC=C21 Chemical class N1C=CN=C2N=CC=C21 LJWZSXDLNMOUIP-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000036541 health Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH195091 | 1991-07-02 | ||
| CH166792 | 1992-05-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO922604D0 NO922604D0 (no) | 1992-07-01 |
| NO922604L true NO922604L (no) | 1993-01-04 |
Family
ID=25688329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO92922604A NO922604L (no) | 1991-07-02 | 1992-07-01 | Pyrrolopyraziner |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5292732A (fr) |
| EP (1) | EP0521368A1 (fr) |
| JP (1) | JPH0774217B2 (fr) |
| CN (1) | CN1030986C (fr) |
| AU (1) | AU654362B2 (fr) |
| CA (1) | CA2072836A1 (fr) |
| CS (1) | CS202292A3 (fr) |
| FI (1) | FI100242B (fr) |
| HU (1) | HUT70163A (fr) |
| IE (1) | IE922152A1 (fr) |
| IL (1) | IL102337A (fr) |
| NO (1) | NO922604L (fr) |
| NZ (1) | NZ243310A (fr) |
| TW (1) | TW224974B (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0572863A1 (fr) * | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | Pyrazinoindoles à activité sur le SNC |
| US5378846A (en) * | 1993-06-11 | 1995-01-03 | Russian-American Institute For New Drug Development | 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives |
| US5352096A (en) * | 1993-09-27 | 1994-10-04 | Chi Wen Chen | Air compressor for automobiles |
| TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| UA66370C2 (en) | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
| IL143958A0 (en) | 1998-12-25 | 2002-04-21 | Shionogi & Co | Heteroaromatic derivatives having an inhibitory activity against hiv integrase |
| EP1635641B1 (fr) * | 2003-06-12 | 2009-03-25 | Merck & Co., Inc. | Inhibiteurs de kinesine mitotique |
| EP1741709A1 (fr) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Amides heterocycliques substitués contenant un linker saturé, et leur utilisation comme agent pharmaceutique |
| DE102006049452A1 (de) * | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| DK2580200T3 (en) | 2010-06-09 | 2017-01-09 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H- [1,4] oxazin-3-YLAMINDERIVATER THAT COULD BE USED AS INHIBITORS OF BETA-secretase (BACE) |
| AU2011347377B2 (en) | 2010-12-22 | 2016-03-03 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| ES2558779T3 (es) | 2011-03-01 | 2016-02-08 | Janssen Pharmaceutica, N.V. | Derivados de 6,7-dihidro-pirazolo[1,5-a]piracin-4-ilamina útiles como inhibidores de ß-secretasa (BACE) |
| KR102012675B1 (ko) | 2011-03-09 | 2019-08-21 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(BACE)의 억제제로서 유용한 3,4-디하이드로-피롤로[1,2-a]피라진-1-일아민 유도체 |
| MX2015007940A (es) * | 2012-12-19 | 2016-03-11 | Novartis Ag | Compuestos tricíclicos como inhibidores de cftr. |
| AU2014280125B2 (en) | 2013-06-12 | 2018-03-15 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
| CN105452251B (zh) | 2013-06-12 | 2017-12-26 | 詹森药业有限公司 | 作为β‑分泌酶(BACE)抑制剂的4‑氨基‑6‑苯基‑5,6‑二氢咪唑并[1,5‑A]吡嗪‑3(2H)‑酮衍生物 |
| EP3008066B1 (fr) | 2013-06-12 | 2018-08-15 | Janssen Pharmaceutica N.V. | Dérivés de 4-amino-6-phényl-5,6-dihydroimidazo[1,5-a]pyrazine comme inhibiteurs de bêta-sécrétase (bace) |
| US10106524B2 (en) | 2014-12-18 | 2018-10-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
| CN110709523B (zh) * | 2017-04-12 | 2023-07-11 | 豪夫迈·罗氏有限公司 | 使用经pictet spengler反应获得的加标签的核苷的测序反应方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1185080A (en) * | 1967-12-07 | 1970-03-18 | Beecham Group Ltd | Pyrrolidines |
| US3906010A (en) * | 1974-06-17 | 1975-09-16 | Morton Norwich Products Inc | Series of 5-aryl-2-furamidines |
| US3931247A (en) * | 1974-12-11 | 1976-01-06 | Morton-Norwich Products, Inc. | 5-(Substituted)phenylfurfuryl alcohols |
| JPS5811878B2 (ja) * | 1974-12-19 | 1983-03-04 | 大正製薬株式会社 | フロ （ ３ ２−ｂ ） インド−ルルイノ セイホウ |
| US4188389A (en) * | 1978-11-03 | 1980-02-12 | Ayerst Mckenna & Harrison, Inc. | 1,2,3,4-Tetrahydropyrrolo(1,2-A)pyrazines |
| JPS5852995B2 (ja) * | 1981-09-28 | 1983-11-26 | 武田薬品工業株式会社 | フルフラ−ル誘導体の製造法 |
| US4882354A (en) * | 1987-12-16 | 1989-11-21 | Norwich Eaton Pharmaceuticals, Inc. | N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents |
-
1992
- 1992-06-12 TW TW081104600A patent/TW224974B/zh active
- 1992-06-23 EP EP92110531A patent/EP0521368A1/fr not_active Ceased
- 1992-06-25 NZ NZ243310A patent/NZ243310A/en unknown
- 1992-06-26 IL IL10233792A patent/IL102337A/en not_active IP Right Cessation
- 1992-06-26 US US07/905,584 patent/US5292732A/en not_active Expired - Fee Related
- 1992-06-26 HU HU9202139A patent/HUT70163A/hu unknown
- 1992-06-29 CS CS922022A patent/CS202292A3/cs unknown
- 1992-06-29 AU AU19309/92A patent/AU654362B2/en not_active Ceased
- 1992-06-30 CA CA002072836A patent/CA2072836A1/fr not_active Abandoned
- 1992-07-01 NO NO92922604A patent/NO922604L/no unknown
- 1992-07-01 IE IE215292A patent/IE922152A1/en not_active Application Discontinuation
- 1992-07-02 CN CN92105314A patent/CN1030986C/zh not_active Expired - Fee Related
- 1992-07-02 FI FI923073A patent/FI100242B/fi active
- 1992-07-02 JP JP4197449A patent/JPH0774217B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL102337A (en) | 1996-01-31 |
| CA2072836A1 (fr) | 1993-01-03 |
| AU1930992A (en) | 1993-01-07 |
| HUT70163A (en) | 1995-09-28 |
| FI923073A (fi) | 1993-01-03 |
| IL102337A0 (en) | 1993-01-14 |
| NO922604D0 (no) | 1992-07-01 |
| TW224974B (fr) | 1994-06-11 |
| CN1030986C (zh) | 1996-02-14 |
| CS202292A3 (en) | 1993-01-13 |
| US5292732A (en) | 1994-03-08 |
| AU654362B2 (en) | 1994-11-03 |
| NZ243310A (en) | 1994-11-25 |
| IE922152A1 (en) | 1993-01-13 |
| JPH06239865A (ja) | 1994-08-30 |
| EP0521368A1 (fr) | 1993-01-07 |
| FI923073A0 (fi) | 1992-07-02 |
| JPH0774217B2 (ja) | 1995-08-09 |
| CN1068328A (zh) | 1993-01-27 |
| FI100242B (fi) | 1997-10-31 |
| HU9202139D0 (en) | 1992-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO922604L (no) | Pyrrolopyraziner | |
| CR20200588A (es) | Compuestos novedosos | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| NO20051036L (no) | 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander | |
| EA200400387A1 (ru) | Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний | |
| EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
| KR100634089B1 (ko) | 항박테리아제로서의 히드록삼산 유도체 | |
| MX2022006470A (es) | Tiromimeticos novedosos. | |
| ATE147071T1 (de) | 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung | |
| ATE232529T1 (de) | Substituierte 3-(aminoalkylamino)-1,2- benzisoxazole und verwandte verbindungen | |
| KR950011747B1 (en) | Quinoline carboxylic acid perivatives | |
| GB1099787A (en) | Novel nitro-imidazole derivatives and the manufacture thereof | |
| CA2003665A1 (fr) | Compose pharmaceutique contenant des 1-{mono- ou bis (trifluoromethyl)-2-pyridinyl} piperazines | |
| US12006283B2 (en) | HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient | |
| JPS568319A (en) | Antihistamine | |
| MX2024005670A (es) | Analogos deuterados de acetil-leucina. | |
| HRP20041208A2 (en) | Pyrrolidine derivatives as oxytocin antagonists | |
| NO902439D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser. | |
| GB1046234A (en) | Improvements in or relating to substituted tetrahydronaphthyl nitrogen mustards | |
| GB1060498A (en) | Improvements in or relating to novel thiaxanthene oxide derivatives | |
| GB1265744A (fr) | ||
| NO921723L (no) | Nye kinolinforbindelser, fremgangsmaate for deres fremstilling og deres terapeutiske anvendelse | |
| AU564287B2 (en) | N-propyl,3-(substituted phenyl)piperidine | |
| JP2016006043A (ja) | 新規キノン誘導体およびそれを有効成分とする抗トリパノソーマ剤 | |
| NO932513L (no) | N-alkyl-kinuklidinium-salter |